Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Mikkael Sekeres

Mikkael Sekeres


Academic History

Mikkael Sekeres, MD, MS, is an internationally recognized authority in the field of hematological malignancies. As of January 2021, he has taken on a new position at Sylvester Comprehensive Cancer Center, Miami, FL, as Physician Liaison in Hematology and the Chief of the Division of Hematology at the University of Miami Miller School of Medicine.

Dr Sekeres started his medical career at the University of Pennsylvania School of Medicine, Philadelphia, PA, where he completed his medical degree and master’s degree in Clinical Epidemiology. He trained in internal medicine at Massachusetts General Hospital, Boston, MA, and completed a fellowship in hematology-oncology at the Dana-Farber Cancer Institute, Boston, MA. Prior to his current appointment, Dr Sekeres worked at the Cleveland Clinic Taussig Cancer Center, Cleveland, OH, taking on several leadership positions including Director of the Leukemia Program in the Department of Hematologic Oncology and Blood Disorders. Dr Sekeres is well known and respected for his work, having spoken at numerous conferences and published extensively. He serves on the editorial board for several journals and is Editor-in-Chief of the ASH Clinical News magazine. Notably, he is an essayist for The New York Times and Huffington Post, and has authored/co-authored several books, including ‘When blood breaks down: Life lesson from Leukemia’, published in 2020. Dr Sekeres is a member of several societies, including ASH and ASCO, and chairs the medical advisory board for the Aplastic Anemia and Myelodysplastic Syndromes International Foundation.

Speaking on molecular alterations and targeted treatments for MDS

Specializing in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), Dr Sekeres’ work has changed clinical practice for these patients. His research has led to the development of novel therapies for AML and MDS, redefined prognostication, and described the molecular biology and epidemiology of these conditions. He has also been a primary investigator for several early phase clinical trials in myeloid malignancies. Dr Sekeres is known as a force for growth and innovation; he has conducted defining research into molecular changes and their clinical correlations, and developed innovative prognostic methods using artificial intelligence.